A comparison of an ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.

Iglesias, Juan F; Muller, Olivier; Zaugg, Serge; Roffi, Marco; Kurz, David J; Vuilliomenet, André; Weilenmann, Daniel; Kaiser, Christoph; Tapponnier, Maxime; Heg, Dik; Valgimigli, Marco; Eeckhout, Eric; Jüni, Peter; Windecker, Stephan; Pilgrim, Thomas (2018). A comparison of an ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention, 14(6), pp. 692-699. Europa Digital & Publishing 10.4244/EIJ-D-17-00734

Text ahead_of_print_issue-article_JAA-286_EIJ-D-17-00734.pdf - Accepted Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

AIMS

A novel ultrathin-strut biodegradable polymer sirolimus-eluting stent (Orsiro™, Biotronik, Bülach, Switzerland; BP-SES) was shown to be superior to a thin-strut durable polymer everolimus-eluting stent (Xience™ Xpedition/Alpine, Abbott Vascular, Santa Clara, USA; DP-EES) with respect to the primary endpoint of target lesion failure (TLF) at 12 months in the prespecified subgroup of patients with ST-segment elevation myocardial infarction (STEMI) included in the BIOSCIENCE trial. We designed a large-scale, randomized, clinical trial to assess the clinical superiority of ultrathin-strut BP-SES over thin-strut DP-EES among patients with STEMI undergoing primary percutaneous coronary intervention.

METHODS AND RESULTS

BIOSTEMI (NCT02579031) is a prospective, multicentre, randomized, controlled, superiority trial that will randomly assign 1'250 patients with STEMI undergoing primary percutaneous coronary intervention to treatment with BP-SES or DP-EES. The primary endpoint of TLF, a composite of cardiac death, target vessel re-infarction, and clinically-indicated target lesion revascularisation within 12 months, will be analysed with Bayesian models applied to the BIOSTEMI dataset (n=1'250) using robustified historical priors to incorporate historical information from the BIOSCIENCE STEMI subgroup (n=407).

CONCLUSIONS

The BIOSTEMI trial will determine whether ultrathin-strut BP-SES are superior to thin-strut DP-EES with respect to TLF in patients with STEMI undergoing primary percutaneous coronary intervention.

Interest & Impact

Downloads

3 since deposited on 08 Feb 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item